Scientists evaluating the prescription drug Otezla recently said it provided “significant" improvement to patients suffering from moderate plaque psoriasis, a condition the National Psoriasis Foundation says affects 7.5 million people across the United States.
The Food and Drug Administration (FDA) has accepted Celgene Corp.'s new drug application for Enasidenib, a treatment for patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation.
Researchers from the University of California San Francisco Medical Center recently stated that, in honor of World MS Day, they want to design more therapies that will help patients with multiple sclerosis (MS) achieve greater independence.
The Leukemia and Lymphoma Society (LLS), Patient Power and MDS Alliance have developed a partnership for the first annual AML (acute myeloid leukemia) Awareness Day, designed to increase awareness of the disease.
Responsibility to patients is a central concern for Celgene Corp., a biotechnology company based in Summit, New Jersey, that specializes in the development of therapies for cancer and inflammatory disorders.